{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T13:41:33Z","timestamp":1789047693549,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","clinicalnutritionespen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Nutrition ESPEN"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.clnesp.2024.09.002","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T15:42:54Z","timestamp":1725637374000},"page":"44-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Relationship between energetic gap and sensitivity to anti-programmed cell death 1 immune checkpoint inhibitors in non-small cell lung cancer patients: The ELY-2 study"],"prefix":"10.1016","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6964-9113","authenticated-orcid":false,"given":"Manuela Tiako","family":"Meyo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascaline","family":"Boudou-Rouquette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Arrondeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne Qiong","family":"Yu Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1406-653X","authenticated-orcid":false,"given":"Nathalie","family":"Neveux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1244-873X","authenticated-orcid":false,"given":"Elizabeth","family":"Fabre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Guidet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Damotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Wislez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Alexandre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Durand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7649-2169","authenticated-orcid":false,"given":"Guillaume","family":"Ulmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Goldwasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.clnesp.2024.09.002_bib1","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.clnesp.2024.09.002_bib2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.clnesp.2024.09.002_bib3","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.clnesp.2024.09.002_bib4","doi-asserted-by":"crossref","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","article-title":"Non-small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Ettinger","year":"2022","journal-title":"J\u00a0Natl Compr Cancer Netw JNCCN"},{"issue":"2","key":"10.1016\/j.clnesp.2024.09.002_bib5","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1177\/0148607113502674","article-title":"Prevalence of malnutrition and current use of nutrition support in patients with cancer","volume":"38","author":"H\u00e9buterne","year":"2014","journal-title":"JPEN - J Parenter Enter Nutr"},{"issue":"4","key":"10.1016\/j.clnesp.2024.09.002_bib6","first-page":"3119","article-title":"The prevalence of CT-defined low skeletal muscle mass in patients with metastatic cancer: a cross-sectional multicenter French study (the SCAN study)","volume":"30","author":"Raynard","year":"2022","journal-title":"Support Care Cancer Off J Multinatl Assoc Support Care Cancer"},{"issue":"4","key":"10.1016\/j.clnesp.2024.09.002_bib7","doi-asserted-by":"crossref","DOI":"10.1111\/ecc.12503","article-title":"High prevalence of malnutrition and deranged relationship between energy demands and food intake in advanced non-small cell lung cancer","volume":"26","author":"Mohan","year":"2017","journal-title":"Eur J Cancer Care (Engl)."},{"issue":"4","key":"10.1016\/j.clnesp.2024.09.002_bib8","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.clnu.2017.07.010","article-title":"Prevalence and predictive value of pre-therapeutic sarcopenia in cancer patients: a systematic review","volume":"37","author":"Pamoukdjian","year":"2018","journal-title":"Clin Nutr"},{"key":"10.1016\/j.clnesp.2024.09.002_bib9","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ejca.2015.12.030","article-title":"Prognostic value of sarcopenia in adults with solid tumours: a meta-analysis and systematic review","volume":"57","author":"Shachar","year":"2016","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.clnesp.2024.09.002_bib10","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1093\/ajcn\/40.1.168","article-title":"The Harris Benedict equation reevaluated: resting energy requirements and the body cell mass","volume":"40","author":"Roza","year":"1984","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"10.1016\/j.clnesp.2024.09.002_bib11","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/jpen.1310","article-title":"Accuracy of a portable indirect calorimeter for measuring resting energy expenditure in individuals with cancer","volume":"43","author":"Purcell","year":"2019","journal-title":"JPEN - J Parenter Enter Nutr"},{"issue":"5","key":"10.1016\/j.clnesp.2024.09.002_bib12","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3945\/ajcn.116.140434","article-title":"Relation between hypermetabolism, cachexia, and survival in cancer patients: a prospective study in 390 cancer patients before initiation of anticancer therapy","volume":"105","author":"Vazeille","year":"2017","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.clnesp.2024.09.002_bib13","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.clnesp.2021.01.019","article-title":"Resting energy expenditure in cancer patients: agreement between predictive equations and indirect calorimetry","volume":"42","author":"Barcellos","year":"2021","journal-title":"Clin Nutr ESPEN"},{"issue":"4","key":"10.1016\/j.clnesp.2024.09.002_bib14","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/jcsm.12080","article-title":"Hypermetabolism: should cancer types, pathological stages and races be considered in assessing metabolism and could elevated resting energy expenditure be the therapeutic target in patients with advanced cancer?: correspondence","volume":"6","author":"Ishida","year":"2015","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.clnesp.2024.09.002_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103630","volume":"73","author":"Boudou-Rouquette","year":"2021","journal-title":"EBioMedicine"},{"issue":"13","key":"10.1016\/j.clnesp.2024.09.002_bib16","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.3390\/cancers14133214","article-title":"Association of energy expenditure and efficacy in metastatic renal cell carcinoma patients treated with nivolumab","volume":"14","author":"Noel","year":"2022","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.clnesp.2024.09.002_bib17","first-page":"558","article-title":"Resting energy expenditure in the risk assessment of anticancer treatments","volume":"37","author":"Jouinot","year":"2018","journal-title":"Clin Nutr Edinb Scotl"},{"issue":"1","key":"10.1016\/j.clnesp.2024.09.002_bib18","first-page":"4","article-title":"Indirect calorimetry: the 6 main issues","volume":"40","author":"Achamrah","year":"2021","journal-title":"Clin Nutr Edinb Scotl"},{"issue":"4","key":"10.1016\/j.clnesp.2024.09.002_bib19","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0021-9258(18)85715-5","article-title":"Summary of the basal metabolism data on 8,614 subjects with especial reference to the normal standards for the estimation of the basal metabolic rate","volume":"54","author":"Boothby","year":"1922","journal-title":"J\u00a0Biol Chem"},{"issue":"1","key":"10.1016\/j.clnesp.2024.09.002_bib20","first-page":"72","article-title":"Resting energy expenditure and body composition in patients with newly detected cancer","volume":"29","author":"Cao","year":"2010","journal-title":"Clin Nutr Edinb Scotl"},{"issue":"6","key":"10.1016\/j.clnesp.2024.09.002_bib21","first-page":"1893","article-title":"Hypermetabolism is an independent prognostic factor of survival in metastatic non-small cell lung cancer patients","volume":"39","author":"Jouinot","year":"2020","journal-title":"Clin Nutr Edinb Scotl"},{"issue":"6","key":"10.1016\/j.clnesp.2024.09.002_bib22","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1093\/ajcn\/37.6.986","article-title":"Source of variance in 24-hour dietary recall data: implications for nutrition study design and interpretation. Carbohydrate sources, vitamins, and minerals","volume":"37","author":"Beaton","year":"1983","journal-title":"Am J Clin Nutr"},{"issue":"8","key":"10.1016\/j.clnesp.2024.09.002_bib23","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1093\/annonc\/mdx235","article-title":"Assessment of nivolumab benefit\u2013risk profile of a 240-mg flat dose relative to a 3-mg\/kg dosing regimen in patients with advanced tumors","volume":"28","author":"Zhao","year":"2017","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.clnesp.2024.09.002_bib24","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.clnesp.2024.09.002_bib25","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000504874","article-title":"Lean body mass and endocrine status but not age are determinants of resting energy expenditure in patients with non-small cell lung cancer","volume":"75","author":"Ulmann","year":"2019","journal-title":"Ann Nutr Metab"},{"key":"10.1016\/j.clnesp.2024.09.002_bib26","volume":"16","author":"Bellesoeur","year":"2019"},{"issue":"2","key":"10.1016\/j.clnesp.2024.09.002_bib27","article-title":"Predictive value of soluble PD-1, PD-L1, VEGFA, CD40 ligand and CD44 for nivolumab therapy in advanced non-small cell lung cancer: a case-control study","volume":"12","author":"Tiako","year":"2020","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.clnesp.2024.09.002_bib28","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/S1470-2045(19)30407-3","article-title":"Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis","volume":"20","author":"Antonia","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.clnesp.2024.09.002_bib29","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clnesp.2024.09.002_bib30","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1186\/s12967-019-2100-3","article-title":"The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort","volume":"17","author":"Damotte","year":"2019","journal-title":"J\u00a0Transl Med"},{"issue":"26","key":"10.1016\/j.clnesp.2024.09.002_bib31","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1200\/JCO.2010.31.5143","article-title":"Host factors and cancer outcome","volume":"28","author":"Goodwin","year":"2010","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.clnesp.2024.09.002_bib32","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ejca.2019.11.003","article-title":"The impact of body composition parameters on severe toxicity of nivolumab","volume":"124","author":"Hirsch","year":"1990","journal-title":"Eur J Cancer Oxf Engl"},{"issue":"4","key":"10.1016\/j.clnesp.2024.09.002_bib33","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s10637-017-0464-x","article-title":"Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients","volume":"35","author":"Heidelberger","year":"2017","journal-title":"Invest N Drugs"},{"issue":"6371","key":"10.1016\/j.clnesp.2024.09.002_bib34","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.clnesp.2024.09.002_bib35","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41591-021-01655-5","article-title":"Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer","volume":"28","author":"Derosa","year":"2022","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.clnesp.2024.09.002_bib36","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1080\/19490976.2018.1527167","article-title":"The intimate relationship between gut microbiota and cancer immunotherapy","volume":"10","author":"Elkrief","year":"2019","journal-title":"Gut Microb"},{"issue":"2","key":"10.1016\/j.clnesp.2024.09.002_bib37","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.eururo.2020.04.044","article-title":"Gut bacteria composition drives primary resistance to cancer immunotherapy in renal cell carcinoma patients","volume":"78","author":"Derosa","year":"2020","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.clnesp.2024.09.002_bib38","doi-asserted-by":"crossref","first-page":"6375","DOI":"10.18632\/aging.202739","article-title":"Oral administration of Akkermansia muciniphila elevates systemic antiaging and anticancer metabolites","volume":"13","author":"Grajeda-Iglesias","year":"2021","journal-title":"Aging"},{"issue":"6529","key":"10.1016\/j.clnesp.2024.09.002_bib39","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1126\/science.abb5920","article-title":"Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients","volume":"371","author":"Baruch","year":"2021","journal-title":"Science"},{"issue":"13","key":"10.1016\/j.clnesp.2024.09.002_bib40","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1016\/j.cell.2024.05.029","article-title":"Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome","volume":"187","author":"Derosa","year":"2024","journal-title":"Cell"},{"issue":"6155","key":"10.1016\/j.clnesp.2024.09.002_bib41","doi-asserted-by":"crossref","DOI":"10.1126\/science.1242454","article-title":"Fueling immunity: insights into metabolism and lymphocyte function","volume":"342","author":"Pearce","year":"2013","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.clnesp.2024.09.002_bib42","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.clnesp.2024.09.002_bib43","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1158\/2326-6066.CIR-23-0739","article-title":"Iron boosts anti-tumor type 1 T-cell responses and anti-PD1 immunotherapy","volume":"12","author":"Porte","year":"2024","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"10.1016\/j.clnesp.2024.09.002_bib44","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.immuni.2016.07.009","article-title":"The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction","volume":"45","author":"Scharping","year":"2016","journal-title":"Immunity"}],"container-title":["Clinical Nutrition ESPEN"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405457724013019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405457724013019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T12:43:36Z","timestamp":1733143416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405457724013019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":44,"alternative-id":["S2405457724013019"],"URL":"https:\/\/doi.org\/10.1016\/j.clnesp.2024.09.002","relation":{},"ISSN":["2405-4577"],"issn-type":[{"value":"2405-4577","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relationship between energetic gap and sensitivity to anti-programmed cell death 1 immune checkpoint inhibitors in non-small cell lung cancer patients: The ELY-2 study","name":"articletitle","label":"Article Title"},{"value":"Clinical Nutrition ESPEN","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clnesp.2024.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd on behalf of European Society for Clinical Nutrition and Metabolism.","name":"copyright","label":"Copyright"}]}}